66962-62-7

Upstream product

• 1142-20-7 N-Cbz-Ala 
• 66962-55-8 1,2',6'-tri-N-(benzyloxycarbonyl)fortimicin B 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 55779-06-1 fortimicin A 
• 54783-95-8 fortimicin B 
• 66962-56-9 1,2',6',2''-tetra-N-benzyloxycarbonyl-4-N-methyl-fortimicin A 
• 26607-51-2 N-benzyloxycarbonyl-D-alanine 

Downstream Products

• 66962-81-0 (S)-2-Amino-N-{(1S,2R,3R,4S,5S,6R)-4-amino-3-[(2R,3R,6S)-3-amino-6-(1-amino-ethyl)-tetrahydro-pyran-2-yloxy]-2,5-dihydroxy-6-methoxy-cyclohexyl}-N-methyl-propionamide; hydrochloride 
• 66962-81-0 (R)-2-Amino-N-{(1S,2R,3R,4S,5S,6R)-4-amino-3-[(2R,3R,6S)-3-amino-6-(1-amino-ethyl)-tetrahydro-pyran-2-yloxy]-2,5-dihydroxy-6-methoxy-cyclohexyl}-N-methyl-propionamide; hydrochloride 

Relevant academic research and scientific papers

4-N-acylfortimicins B and the preparation of fortimicin A from fortimicin B.

Selective 4-N-acylation of fortimicin B (2) has been accomplished by 4-N-acylation of 1,2',6'-tri-N-benzyloxycarbonylfortimicin B (4) followed by hydrogenolysis of the N-protecting benzyloxycarbonyl groups. In this manner, fortimicin B was converted into fortimicin A (1), and a series of 4-N-acylfortimicins B (3) was prepared for antibacterial assay. The key intermediate, 1,2',6'-tri-N-benzyloxycarbonylfortimicin B, was prepared either directly from fortimicin B or by converting fortimicin A into 1,2',6',2''-tetra-N-benzyloxycarbonylfortimicin A (6a), followed by selective hydrolysis of the 4-N-(N-benzyloxycarbonyl)glycyl group of the latter.